Recruiting

Testing a new combination treatment for early-stage high-risk breast cancer

Plain-English translation of NCT06966700 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Read our Breast Neoplasms research guide →

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether —a new targeted therapy that attacks specific proteins on cancer cells—works better when combined with immunotherapy () and standard chemotherapy than chemotherapy and immunotherapy alone. The goal is to help people with early-stage, high-risk breast cancer that doesn't have certain growth-promoting proteins. Researchers want to see if this combination shrinks tumors more effectively and keeps the cancer from returning.

Some types of breast cancer are harder to treat because they lack proteins that doctors usually target with existing therapies. This trial is testing whether the new targeted medication can fill that gap and improve outcomes for people with these difficult-to-treat cancers.

Do you qualify?

You likely qualify if…

you have been diagnosed with early-stage, high-risk breast cancer that is either triple-negative or hormone receptor-low
your cancer has not spread beyond your breast and nearby lymph nodes
you have not received any prior treatment for this cancer, including surgery, chemotherapy, or radiation
you are in good overall health with adequate organ function
you are able to provide a tissue sample from your tumor for testing

You likely don't qualify if…

your cancer has spread to other parts of your body (Stage IV)
you have previously received chemotherapy, immunotherapy, or other cancer treatments
you have received a live vaccine within the past month
you have a history of serious lung problems that required steroid treatment
you have another active cancer that is being treated or has required treatment in the past 5 years

What participation looks like

You would receive intravenous infusions of the medication, immunotherapy, and chemotherapy over about 6 months before surgery. During this time, you'll have regular hospital or clinic visits for treatment and monitoring. After surgery, you'll continue receiving immunotherapy infusions for several more months. Throughout the trial, you'll have blood tests, imaging scans, and check-ups to monitor your health and how well the treatment is working.

Testing a new combination treatment for early-stage high-risk breast cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(317 sites)